Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terri Warren

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Sexually Transmitted Diseases|March 17, 2006
Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral sheddingAnna Wald, Stacy Selke, Terri Warren, et al.
Sexually Transmitted Diseases|March 26, 2008
One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infectionJoseph B Bavaro, Linda Drolette, David M Koelle, et al.
JAMA|April 14, 2011
Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infectionElizabeth Tronstein, Christine Johnston, Meei-Li Huang, et al.
The Journal of Infectious Diseases|September 21, 2004
Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tractRachna Gupta, Anna Wald, Elizabeth Krantz, et al.
Clinical and Vaccine Immunology : CVI|March 21, 2008
Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjectsDavid M Koelle, Amalia Magaret, Christopher L McClurkan, et al.
The Journal of Infectious Diseases|September 27, 2003
Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjectsEdwin DeJesus, Anna Wald, Terri Warren, et al.
Sexually Transmitted Diseases|September 7, 2017
Performance of Commercial Enzyme-Linked Immunoassays for Diagnosis of Herpes Simplex Virus-1 and Herpes Simplex Virus-2 Infection in a Clinical SettingElfriede Agyemang, Quynh-An Le, Terri Warren, et al.
Genes and Immunity|November 18, 2016
HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesionsAmalia Magaret, Lichun Dong, Mina John, et al.
The Journal of Infectious Diseases|February 4, 2011
Persistent genital herpes simplex virus-2 shedding years following the first clinical episodeWarren Phipps, Misty Saracino, Amalia Magaret, et al.
Vaccine|September 28, 2011
Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive personsAnna Wald, David M Koelle, Kenneth Fife, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Sexually Transmitted Diseases|March 17, 2006
Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral sheddingAnna Wald, Stacy Selke, Terri Warren, et al.
Sexually Transmitted Diseases|March 26, 2008
One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infectionJoseph B Bavaro, Linda Drolette, David M Koelle, et al.
JAMA|April 14, 2011
Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infectionElizabeth Tronstein, Christine Johnston, Meei-Li Huang, et al.
The Journal of Infectious Diseases|September 21, 2004
Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tractRachna Gupta, Anna Wald, Elizabeth Krantz, et al.
Clinical and Vaccine Immunology : CVI|March 21, 2008
Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjectsDavid M Koelle, Amalia Magaret, Christopher L McClurkan, et al.
The Journal of Infectious Diseases|September 27, 2003
Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjectsEdwin DeJesus, Anna Wald, Terri Warren, et al.
Sexually Transmitted Diseases|September 7, 2017
Performance of Commercial Enzyme-Linked Immunoassays for Diagnosis of Herpes Simplex Virus-1 and Herpes Simplex Virus-2 Infection in a Clinical SettingElfriede Agyemang, Quynh-An Le, Terri Warren, et al.
Genes and Immunity|November 18, 2016
HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesionsAmalia Magaret, Lichun Dong, Mina John, et al.
The Journal of Infectious Diseases|February 4, 2011
Persistent genital herpes simplex virus-2 shedding years following the first clinical episodeWarren Phipps, Misty Saracino, Amalia Magaret, et al.
Vaccine|September 28, 2011
Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive personsAnna Wald, David M Koelle, Kenneth Fife, et al.
Pageof 4